| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6820750 | Schizophrenia Research | 2018 | 7 Pages |
Abstract
Among patients with schizophrenia, LAI use is associated with an approximately 30% lower risk of death compared with oral agents. SG LAIs and oral aripiprazole are associated with the lowest mortality.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Heidi Taipale, Ellenor Mittendorfer-Rutz, Kristina Alexanderson, Maila Majak, Juha Mehtälä, Fabian Hoti, Erik Jedenius, Dana Enkusson, Amy Leval, Jan Sermon, Antti Tanskanen, Jari Tiihonen,